

RENALYTIX AI

Notice of results

August 20, 2019

Download [full announcement](#)

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence clinical *in vitro* diagnostics for kidney disease, announces that it will release its preliminary results for the year ended 30 June 2019 on Tuesday, 3 September 2019.

Analyst briefing

An analyst briefing will take place at 1pm on Tuesday, 3 September 2019. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email renalytix@walbrookpr.com

Investor briefing

A briefing open to all investors will take place on Tuesday, 3 September 2019 at the Brand Exchange, 3 Birchin Lane, London EC3V 9BW from 5.15pm for a 5.30pm start and will be followed by light refreshments. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email renalytix@walbrookpr.com

Enquiries

Renalytix AI plc

James McCullough, CEO

www.renalytixai.com

Via Walbrook PR or
Tel: +1 646 397 3970

Stifel (Nominated Adviser & Joint Broker)

Tel: 020 7710 7600

Alex Price / Jonathan Senior / Ben Maddison (Investment Banking)
Peter Lees (Corporate Broking)

N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / James White / George Tzimas (Corporate Finance)
Tom Salvesen / Mia Gardner (Corporate Broking)

Walbrook PR Limited

Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780
renalytix@walbrookpr.com
Mob: 07980 541 893
07584 391 303